Niacin conjugated fatty acid mixtures and their uses

A pharmaceutical composition comprising a mixture of a niacin-EPA conjugate and a niacin-DHA conjugate wherein a niacin is linked to either DHA or EPA via a linker having the formula:

• wherein, each a, b, c, and d is independently —H, -D, —CH3, —OCH3, —OCH2CH3, —C(O)OR, or benzyl;
• up to two of a, b, c, and d can be —OZ;
• or two of a, b, c, and d can be taken together, along with the single carbon to which they are bound, to form a cycloalkyl or heterocycle;
• m is 0, 1, 2, or 3;
• each n, o, p, and q is independently 0 or 1;
• each L is independently —O—, —S—, —S(O)—, —S(O)2—, —S—S—,
• wherein when m is 2 or 3, up to one of the heteroatoms —O—, —S—, —S(O)—, —S(O)2—, —S—S— can be selected for L;
• each g is independently 2, 3 or 4;
• each h is independently 1, 2, 3 or 4;
• each R6 is independently H or C1-C6 alkyl, or both R6 groups, when taken together with the nitrogen to which they are attached, form a heterocycle;
• each R7 is independently e, H, or straight or branched C1-C10 alkyl which can be optionally substituted with OH, NH2, CO2R, CONH2, phenyl, C6H4OH, imidazole or arginine;
• each e is independently H or any one of the side chains of a naturally occurring amino acid;
• each R is independently —H, —C(O)—C1-C3 alkyl, or straight or branched C1-C4 alkyl optionally substituted with halogen;
• wherein Z is independently —H, or
• each r is independently 2, 3, or 7;
• each s is independently 3, 5, or 6;
• each t is independently 0 or 1;
• each v is independently 1, 2, or 6;
• and
• R4 and R5 are each independently —H, -D, -C1—C4 alkyl, -halogen, —OH, —C(O)C1-C4 alkyl, —O-aryl, -O-benzyl, —OC(O)C1-C4 alkyl, —C2-C3 alkene, —C2-C3 alkyne, 13 NH2, —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, —NH(C(O)C1-C3 alkyl), —N(C(O)C1-C3 alkyl)2, —SH, —S(C1-C3 alkyl), —S(O)C1-C3 alkyl, or —S(O)2C1-C3 alkyl.